CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

AIM2-driven inflammasome activation in heart failure SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure Glucose-lowering Drugs or Strategies, Atherosclerotic Cardiovascular Events, and Heart Failure in People With or at Risk of Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis of Randomised Cardiovascular Outcome Trials Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5) Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

Original Research2021 Jun 12;cvab202.

JOURNAL:Cardiovasc Res. Article Link

AIM2-driven inflammasome activation in heart failure

Z Onódi, M Ruppert, D Kucsera et al. Keywords: canakinumab; cardiomyopathy; drug repurposing; heart failure; inflammation; probenecid

Full Text PDF